Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone512-519-0400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.12 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/28/2019 (Confirmed)
OptionableOptionable
Vermillion (NASDAQ:VRML) Frequently Asked Questions
What is Vermillion's stock symbol?
Vermillion trades on the NASDAQ under the ticker symbol "VRML."
How were Vermillion's earnings last quarter?
Vermillion, Inc. (NASDAQ:VRML) posted its earnings results on Thursday, August, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.04). The company had revenue of $0.71 million for the quarter. Vermillion had a negative return on equity of 174.33% and a negative net margin of 392.83%. View Vermillion's Earnings History.
When is Vermillion's next earnings date?
What price target have analysts set for VRML?
1 Wall Street analysts have issued 12-month price objectives for Vermillion's stock. Their forecasts range from $2.25 to $2.25. On average, they anticipate Vermillion's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price. View Analyst Price Targets for Vermillion.
What is the consensus analysts' recommendation for Vermillion?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vermillion in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vermillion.
Has Vermillion been receiving favorable news coverage?
News articles about VRML stock have been trending neutral on Friday, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vermillion earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.
Are investors shorting Vermillion?
Vermillion saw a increase in short interest during the month of February. As of February 15th, there was short interest totalling 777,521 shares, an increase of 45.8% from the January 31st total of 533,311 shares. Based on an average trading volume of 71,172 shares, the days-to-cover ratio is currently 10.9 days. Currently, 1.8% of the company's shares are sold short. View Vermillion's Current Options Chain.
Who are some of Vermillion's key competitors?
Some companies that are related to Vermillion include Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Akers Biosciences (AKER), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD) and Response Genetics (RGDXQ).
What other stocks do shareholders of Vermillion own?
Who are Vermillion's key executives?
Vermillion's management team includes the folowing people:
- Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 58)
- Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 56)
- Mr. Chris Goulart, Sr. VP of Commercial Operations
Who are Vermillion's major shareholders?
Vermillion's stock is owned by many different of retail and institutional investors. Top institutional investors include Birchview Capital LP (2.80%), Essex Investment Management Co. LLC (0.45%), Essex Investment Management Co. LLC (0.45%), Greenwich Wealth Management LLC (0.32%) and B. Riley Wealth Management Inc. (0.24%). Company insiders that own Vermillion stock include David Schreiber, Jack W Schuler, James T Lafrance, Robert Harry Beechey and Valerie Barber Palmieri. View Institutional Ownership Trends for Vermillion.
Which major investors are selling Vermillion stock?
VRML stock was sold by a variety of institutional investors in the last quarter, including Birchview Capital LP. Company insiders that have sold Vermillion company stock in the last year include David Schreiber and James T Lafrance. View Insider Buying and Selling for Vermillion.
Which major investors are buying Vermillion stock?
VRML stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Essex Investment Management Co. LLC, B. Riley Wealth Management Inc. and Greenwich Wealth Management LLC. Company insiders that have bought Vermillion stock in the last two years include Jack W Schuler, Robert Harry Beechey and Valerie Barber Palmieri. View Insider Buying and Selling for Vermillion.
How do I buy shares of Vermillion?
Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vermillion's stock price today?
One share of VRML stock can currently be purchased for approximately $1.36.
How big of a company is Vermillion?
Vermillion has a market capitalization of $102.52 million and generates $3.12 million in revenue each year.
What is Vermillion's official website?
How can I contact Vermillion?
Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]
MarketBeat Community Rating for Vermillion (NASDAQ VRML)
MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe VRML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days.
